How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pseudomonas-aeruginosa-urinary-tract-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pseudomonas Aeruginosa Urinary Tract Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pseudomonas Aeruginosa Urinary Tract Infection (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pseudomonas Aeruginosa Urinary Tract Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Pseudomonas Aeruginosa Urinary Tract Infection
Pai Holdings Pharm · 2 drugs in Pseudomonas Aeruginosa Urinary Tract Infection
Bayer AG · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Bristol-Myers Squibb · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Dr Reddys Labs Inc · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Poitiers University Hospital · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Sterimax · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Tel-Aviv Sourasky Medical Center · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Pseudomonas Aeruginosa Urinary Tract Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pseudomonas Aeruginosa Urinary Tract Infection:

Cite this brief

Drug Landscape (2026). Pseudomonas Aeruginosa Urinary Tract Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudomonas-aeruginosa-urinary-tract-infection. Accessed 2026-06-10.

Pseudomonas Aeruginosa Urinary Tract Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing